
- ONCOLOGY Vol 40, Issue 8
- Volume 40
- Issue 8
- Pages: 251-255
3 Things You Should Know About MET-Altered NSCLC
Learn how to classify MET dysregulation in NSCLC, match alterations to targeted therapies, and manage adverse events from c-Met–directed agents including antibody-drug conjugates.
LEARNING OBJECTIVES
Upon successful completion of this activity, you should be better prepared to:
• Assess molecular testing strategies for identifying categories of MET alterations in patients with non–small cell lung cancer (NSCLC)
• Evaluate emerging clinical evidence for next-generation c-Met–targeting agents and combination strategies in MET-dysregulated NSCLC
• Develop evidence-based approaches to identify and manage adverse events associated with c-Met–directed therapies, including those specific to antibody-drug conjugates
RELEASE DATE: October 7, 2026
EXPIRATION DATE: October 7, 2027
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from AbbVie, Inc.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off-label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.
INSTRUCTIONS FOR PARTICIPATION and HOW TO RECEIVE CREDIT
1. Read this activity in its entirety.
2. Go to
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
YOU MAY IMMEDIATELY DOWNLOAD YOUR CERTIFICATE.
Many non–small cell lung cancers (NSCLC) exhibit MET dysregulation: c-Met protein overexpression, MET amplification (de novo or following tyrosine kinase inhibitor [TKI] therapy), and/or MET exon 14 skipping mutations.1,2 The most common, c-Met protein overexpression, requires separate immunohistochemistry (IHC) testing. To unlock the power of targeted therapy, MET dysregulation must be accurately classified and matched with the most effective drug. Sanja Dacic, MD, PhD, and Deborah Doroshow, MD, PhD, address treatment selection and adverse event management, answering your top 3 questions about MET-targeted therapies for advanced NSCLC (aNSCLC).
1) If next-generation sequencing has already detected MET amplification or an exon 14 skipping mutation, do you still order the c-Met IHC? What is the protein assay telling us that the genomic assay isn’t? If the c-Met IHC is 3+ and a high gene copy number (GCN) is detected, would you use an antibody-drug conjugate (ADC)?
Dacic / All the mechanisms you mentioned—MET amplification, MET exon 14 mutations—can lead to upregulation and overexpression of the c-Met protein. But there is no perfect correlation. Some cases with MET exon 14 skipping may not overexpress Met protein.3 With amplification, the correlation is usually better4; particularly with high-level amplification, it’s going to be a high level of overexpression. But these are different mechanisms of MET alterations. Each has a different group of drugs (Table),1,2,5 so the oncologist decides how to treat these patients, accounting for line of treatment and other considerations.
Dacic / What’s the best assay? With ADCs, we are looking for expression of the target—where it is present in the cell, on the surface, and how much is actually there. And protein overexpression by IHC is the only method that can answer that.
In May 2025, the FDA granted accelerated approval to the c-Met–directed ADC telisotuzumab vedotin (Teliso-V) for nonsquamous (NSQ) aNSCLC with high c-Met protein overexpression (≥ 50% of tumor cells with strong [3+] staining) after prior systemic therapy.6 In the phase 2 LUMINOSITY study (NCT03539536), Teliso-V monotherapy demonstrated an objective response rate (ORR) of 34.5% and median duration of response (DOR) of 7.2 months in NSQ, EGFR wild-type aNSCLC with high c-Met protein overexpression.7 A retrospective LUMINOSITY subgroup analysis defined MET amplification as follows: MET/CEP7 greater than or equal to 2.0 with MET GCN greater than or equal to 4 on fluorescence in situ hybridization or plasma MET GCN greater than or equal to 4 with no coamplification in CDK6 and EGFR.8 This analysis revealed MET amplification in 22% of c-Met–intermediate (25% to 49% of tumor cells with strong [3+] staining) and 45% of c-Met–high overexpressing tumors. The ORRs of Teliso-V were 28% and 39% in MET amplification–negative and –positive c-Met overexpressing tumors, respectively.
2) For a patient with EGFR-mutant aNSCLC who progresses on osimertinib and is found to have high-level MET amplification, how do you decide between combined EGFR and MET inhibition vs chemotherapy?
MET amplification may co-occur with sensitizing EGFR mutations de novo or as an adaptive resistance mechanism to EGFR-targeted TKI treatment (Figure 1).9-11 The bispecific EGFR/MET–targeting antibody amivantamab plus carboplatin/pemetrexed is FDA approved for aNSCLC with an EGFR exon 19 deletion or exon 21 L858R substitution progressing after an EGFR-targeted TKI.12 Amivantamab plus the EGFR-targeting TKI lazertinib is FDA approved for EGFR-mutant aNSCLC in the front line.13 Although adding the MET-targeting TKIs savolitinib or tepotinib to osimertinib has demonstrated benefit after osimertinib progression,14-17 these regimens are not FDA approved as of August 2026.
Doroshow / We can use amivantamab plus chemotherapy.18 We can combine various MET TKIs with osimertinib.14-16 Unfortunately, none has a particularly long DOR or progression-free survival, so benefit remains limited. But we just learned [on August 17, 2026] that savolitinib plus osimertinib in this exact setting was very beneficial.17 So I think it worked. It’s great to have options, but hopefully we’ll have some with even higher response rates, beyond the 40% to 50% range, and longer DOR.
Doroshow / As for the osimertinib, if a patient has really good [central nervous system] control, I would not be anxious to stop it.19 Versus if we’re seeing multifocal progression and/or progression in the brain, especially if repeat biopsies suggest a C797S mutation or something else that would cause resistance to osimertinib,20 those would push me toward discontinuing the osimertinib.
3) For ADC-associated ocular toxicity, what practical steps establish prophylaxis and monitoring, and when should the ophthalmology department get involved? How do you manage grade 3 peripheral neuropathy in a patient receiving Teliso-V?
Doroshow / Let’s start with the ophthalmologic question. Many of our ADCs are associated with keratitis and dry eye (Figure 2).5,7,21 This can be really upsetting for patients, causing discomfort and blurry vision. The rate of ocular toxicity depends on the ADC.7,22 The FDA label for Dato-DXd [datopotamab deruxtecan-dlnk] recommends baseline ophthalmologic evaluation and prophylactic artificial tears several times a day.23 On the other hand, the approval for Teliso-V does not mandate a baseline ophthalmologic evaluation or recommend artificial tears.6 I still think artificial tears especially can be helpful adjuncts. I involve an ophthalmologist early and often. I don’t feel comfortable waiting long. Developing a relationship with an ophthalmologist who is comfortable with these toxicities and can see the patient the next day is really the key to managing these toxicities. I can certainly start a patient on artificial tears if they were not on them before, and they were on Teliso-V, for example, but I think they really need to see somebody immediately. If you can’t get a hold of someone immediately, then the emergency room is appropriate because you can get an ophthalmologist to evaluate the patient that day.
Doroshow / Neuropathy is unfortunately one of the more common [adverse] effects of Teliso-V.7 Grade 3 neuropathy is very, very severe. Typically, I don’t see grade 3 neuropathy with any of the treatments I use because we’re monitoring patients very, very closely. I would very much hope that by the time they developed grade 1 or 2 neuropathy, we would have been checking in at every visit, would know about it, and would never let it get to grade 3. That said, sometimes patients don’t tell you when something is bothering them, or something just appears really rapidly, although that’s pretty atypical for neuropathy, which develops over time; it gets worse. It depends on your relationship with the patient and their goals, but certainly with grade 2 neuropathy, which is really any symptom at all, I would hold treatment until it improves to grade 1. Hopefully, no patients get to grade 3, and I would not resume treatment until it reached grade 1 or better.
Key References
7. Girard N, Goldman J, Lu S, et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-met protein overexpressing, nonsquamous, EGFR wild-type advanced NSCLC: updated analysis of the LUMINOSITY trial. JTO Clin Res Rep. 2026;7(7):100988. doi:10.1016/j.jtocrr.2026.100988
17. Tagrisso (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on Tagrisso. News release. AstraZeneca. August 17, 2026. Accessed September 1, 2026. https://www.astrazeneca-us.com/media/press-releases/2026/TAGRISSO-osimertinib-plus-savolitinib-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-MET-driven-EGFR-mutated-lung-cancer-after-progression-on-TAGRISSO.html
18. Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase 3 MARIPOSA-2 study. Ann Oncol. 2024;35(1):77-90. doi:10.1016/j.annonc.2023.10.117
For FULL References List, visit
CME Posttest Questions
1) Which statement best describes the current clinical application of MET protein immunohistochemistry in advanced non–small cell lung cancer (NSCLC)?
A. It identifies candidate tumors for MET-directed antibody-drug conjugates but correlates poorly with underlying MET exon 14 skipping.
B. It serves as a highly sensitive screening triage to rule out genomic MET exon 14 skipping mutations.
C. It accurately differentiates focal low-level gene copy gains from true de novo high-level MET amplification.
D. It utilizes a universally standardized staining cutoff across all laboratories and MET-targeted agents.
2) A patient with EGFR-mutant, nonsquamous NSCLC develops systemic progression after 18 months of first-line osimertinib. Biopsy shows high-level MET amplification (gene copy number ≥ 10); performance status is excellent, and there is no central nervous system progression. Which is the most appropriate next-line systemic therapy?
A. Discontinue osimertinib and initiate capmatinib monotherapy.
B. Continue osimertinib and enroll the patient in a clinical trial combining it with savolitinib.
C. Discontinue osimertinib and initiate platinum-doublet chemotherapy alone.
D. Continue osimertinib alone and escalate the dose to 160 mg daily.
3) A patient on telisotuzumab vedotin develops new-onset grade 3 peripheral neuropathy. Per current FDA labeling, what is the most appropriate next step?
A. Withhold therapy until recovery to grade 2 or lower, then resume at the same dose.
B. Withhold therapy until recovery to grade 1 or lower, then resume at the next lower dose level.
C. Permanently discontinue therapy immediately, without attempting a hold.
D. Continue current dose, adding gabapentin for symptomatic management.
Claim Your CME Credit at
To learn more about this topic, including information on investigational approaches to managing MET dysregulated NSCLC, go to
CME Provider Contact Information
Physicians’ Education Resource®, LLC
259 Prospect Plains Road, Building H
Cranbury, NJ 08512
onc-info@gotoper.com
Articles in this issue
about 1 hour ago
3 Patient Profiles: ADC Therapy in TNBCRelated to this article








